10-year

10-Year Anniversary Promotion (20% off)

Join GuruFocus Premium Membership Now for Only $279/Year

The largest discount in the last 10 years

Save up to $500 on Global Membership.

Don't Miss It !

Free 7-day Trial
All Articles and Columns »

Weekly Guru Bargains Highlights: Huntsman Corp, Manulife Financial Corp, Gilead Sciences Inc, ALERE INC, Coventry Health Care Inc.

July 26, 2010 | About:
guruyt

guruyt

4 followers
Last week's top five guru bargain stocks were Huntsman Corp, Manulife Financial Corp, Gilead Sciences Inc, ALERE INC, and Coventry Health Care Inc. According to GuruFocus updates, these stocks have declined the most since Gurus have bought.

Huntsman Corp. (HUN): Down 22% Since Steven Cohen Bought In the Quarter Ended on 2010-03-31

Steven Cohen added to his holdings in Commodity Chemicals company Huntsman Corp. by 371.24% during the quarter ended 03/31/2010. He owned 170,197 shares of as of 03/31/2010. Huntsman Corporation is among the world's largest global manufacturers of differentiated and commodity chemical products for a variety of industrial and consumer applications. The company has a market cap of $2.36 billion; its shares were traded at around $9.88 with and P/S ratio of 0.3. The dividend yield of Huntsman Corp. stocks is 4.05%.

Huntsman recently reported its first quarter 2010 results. Revenues for the first quarter of 2010 were $2,094 million, an increase of 25% compared to $1,680 million for the same period in 2009 and an increase of 1% compared to $2,065 million for the fourth quarter of 2009.

Michael Price owns 400,000 shares as of 03/31/2010, which accounts for 0.98% of the $490 million portfolio of MFP Investors LLC. Charles Brandes sold out his holdings in the quarter that ended on 03/31/2010. David Einhorn sold out his holdings in the quarter that ended on 03/31/2010.

Buy: Sr. VP, Purchasing Brian V Ridd bought 6,000 shares of HUN stock on 05/20/2010 at the average price of 9.02. Brian V Ridd owns at least 175,209 shares after this. The price of the stock has increased by 9.53% since. There are mixed trades from other insiders.

Manulife Financial Corp. (MFC): Down 24% Since Bruce Kovner Bought In the Quarter Ended on 2010-03-31

Bruce Kovner added to his holdings in Life Insurance company Manulife Financial Corp. by 249.76% during the quarter ended 03/31/2010. He owned 59,480 shares of as of 03/31/2010. Manulife Financial Corporation is the holding company of The Manufacturers Life Insurance Company and its subsidiaries. Manulife Financial Corp. has a market cap of $25.53 billion; its shares were traded at around $14.55 with a P/E ratio of 6.19 and P/S ratio of 0.68. The dividend yield of Manulife Financial Corp. stocks is 3.52%. GuruFocus rated Manulife Financial Corp. the business predictability rank of 4.5-star.

MFC recently reported its first quarter 2010 results. The company announced net income for the first quarter of $1.1 billion. “Our strong sales results for the quarter demonstrated that we are making progress in our ongoing priority of rebalancing our business mix and growing sales in higher return products that will reward our shareholders in the future,” said Donald A. Guloien, president and CEO of MFC.

Gilead Sciences Inc. (GILD): Down 28% Since Paul Tudor Jones Bought In the Quarter Ended on 2010-03-31

Paul Tudor Jones added to his holdings in Biotechnology company Gilead Sciences Inc. by 90.16% during the quarter ended 03/31/2010. He owned 11,600 shares of as of 03/31/2010. Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. Gilead Sciences Inc. has a market cap of $29.74 billion; its shares were traded at around $33.43 with a P/E ratio of 9.83 and P/S ratio of 4.24. Gilead Sciences Inc. had an annual average earning growth of 38.1% over the past 5 years.

On Apr 20, Gilead Sciences, Inc. announced its results of operations for the quarter ended March 31, 2010. The Company announced a revenue of $2.09 billion, net income of $854.9 million, or $0.92 per diluted share, and a non-GAAP net income of $914.8 million, or $0.99 per diluted share.

George Soros owns 62,796 shares as of 03/31/2010, which accounts for 0.04% of the $6.73 billion portfolio of Soros Fund Management LLC. Edward Owens owns 700,000 shares as of 03/31/2010, which accounts for 0.17% of the $18.52 billion portfolio of Vanguard Health Care Fund. Lee Ainslie owns 2,487,642 shares as of 03/31/2010, a decrease of 47.19% of from the previous quarter. This position accounts for 1.21% of the $9.35 billion portfolio of Maverick Capital.

Sell: Chairman and CEO John C Martin sold 100,000 shares of GILD stock on 07/13/2010 at the average price of 35.15. John C Martin owns at least 1,634,042 shares after this. The price of the stock has decreased by 4.89% since. There are mixed trades from other insiders.

ALERE INC. (ALR): Down 34% Since Paul Tudor Jones Bought In the Quarter Ended on 2010-03-31

Paul Tudor Jones initiated holdings in Biotechnology company ALERE INC. during the quarter ended 03/31/2010. He owned 11,900 shares of as of 03/31/2010. Alere Inc. has a market cap of $2.28 billion; its shares were traded at around $27.07 with a P/E ratio of 10.74 and P/S ratio of 1.18.

Private Capital bought 439,805 shares in the quarter that ended on 03/31/2010, which is 1.05% of the $1.63 billion portfolio of Private Capital Management. George Soros owns 25,200 shares as of 03/31/2010, which accounts for 0.01% of the $6.73 billion portfolio of Soros Fund Management LLC. Ron Baron owns 1,058,500 shares as of 03/31/2010, which accounts for 0.27% of the $15.33 billion portfolio of Baron Funds. David Dreman owns 711,268 shares as of 03/31/2010, which accounts for 0.65% of the $4.24 billion portfolio of Dreman Value Management.

Sell: Sr VP, LD & Legal Affairs Paul T Hempel sold 1,145 shares of ALR stock on 05/17/2010 at the average price of 37.04. Paul T Hempel owns at least 8,709 shares after this. The price of the stock has decreased by 26.92% since. Other insiders have also decreased their positions in the company.

Coventry Health Care Inc. (CVH): Down 21% Since Steven Cohen Bought In the Quarter Ended on 2010-03-31

Steven Cohen added to his holdings in Health Care Providers company Coventry Health Care Inc. by 38.93% during the quarter ended 03/31/2010. He owned 38,908 shares of as of 03/31/2010. Coventry Health Care, Inc. is a managed health care company operating health plans under the names Coventry Health Care, Coventry Health and Life, etc. Coventry Health Care Inc. has a market cap of $2.81 billion; its shares were traded at around $19.02 with a P/E ratio of 7.96 and P/S ratio of 0.2. Coventry Health Care Inc. had an annual average earning growth of 28% over the past 10 years. GuruFocus rated Coventry Health Care Inc. the business predictability rank of 2.5-star.

CVH recently reported its first quarter 2010 results. The company reported consolidated operating results for the quarter ended March 31, 2010. Operating revenues totaled $2.9 billion for the quarter with net earnings of $97.3 million, or $0.66 earnings per diluted share (EPS).

Edward Owens owns 8,957,500 shares as of 03/31/2010, which accounts for 1.2% of the $18.52 billion portfolio of Vanguard Health Care Fund. James Barrow owns 3,949,155 shares as of 03/31/2010, which accounts for 0.21% of the $46.38 billion portfolio of Barrow, Hanley, Mewhinney & Strauss. David Dreman owns 10,710 shares as of 03/31/2010, a decrease of 32.56% of from the previous quarter. This position accounts for 0.01% of the $4.24 billion portfolio of Dreman Value Management.

Sell: Sr. VP and Corp. Controller John J Ruhlmann sold 3,205 shares of CVH stock on 06/23/2010 at the average price of 19.39. John J Ruhlmann owns at least 167,386 shares after this. The price of the stock has decreased by 1.91% since.


Rating: 3.6/5 (8 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK